

PatientID	MYCN P	MYCN R	SIX1 P	SIX1 R	WTL P	WTL R	DROSHA P	DROSHA R	DGCR8 P	DGCR8 R	WTX P	WTX R	CTNNB1 P	CTNNB1 R	Other primary	Other relapse	1q P	1q R	11p15 P	11p15 R	12 P	12 R	18 P	18 R	P Exonic mutations	R Exonic mutations	Mutational burden P	Mutational burden R	EFS		
PAUMFA	0.45	0.34													MGA (0)	MGA (0.2)	Gain	Gain			Gain	Gain			13	10	0.50	0.39	380		
PATILY	0	0.41															Gain	Gain			Gain	Gain	Gain		7	15	0.27	0.58	340		
PATEIS	NA	0.45	NA		NA		NA				NA		NA	0.32, 0.27	NA	MGA (0.37)	NA	Gain	NA	CN LOH	NA	Gain	NA		NA	21	NA	0.81	309		
PAVIAG	0	0.46									del						Gain	CN LOH	CN LOH			Gain	Gain		2	9	0.08	0.35	628		
PAWPUL	NA	0.46/Dup	NA		NA		NA				NA		NA		NA	TERT (0.5); HCFC1 (0.19);MAPKB1 (0)	NA	Gain	NA	CN LOH	NA	Gain	NA		NA	34	NA	1.32	674		
PASZNV	dup	dup						0.9	0.88	del	del						Gain	Gain	LOSS	LOSS					6	11	0.23	0.43	283		
PAXELC	dup	dup											0.56	0.41	RBL1 (0)	RBL1 (0.33)		Gain					Gain	Gain	Gain	Gain	23	26	0.89	1.01	187
PAVKGZ	dup	dup													MLLT1 (0.61)	MLLT1 (0.55)									11	13	0.43	0.50	182		
PAVBXS	dup	dup															Gain	Gain							12	15	0.47	0.58	1699		
PAXVZT	NA	dup	NA		NA		NA	0.14	NA	NA	NA	NA	NA	NA	NA	NA	NA	Gain	NA	CN LOH	NA	NA	NA		NA	6	NA	0.23	289		
PAUVCC	NA	dup	NA		NA		NA	0.71	NA	NA	NA	NA	NA	NA	NA	NA	NA	Gain	NA	NA	NA	Gain	NA	Gain	NA	15	NA	0.58	505		
PAVSI	NA		NA	0.65	NA		NA			NA	NA	NA	NA	NA	NA	NA	NA	Gain	NA	NA	NA	Gain	NA		NA	5	NA	0.19	234		
PAWDBN	NA		NA		NA		NA	0.94	NA	NA	NA	NA	NA	NA	NA	MAX (1)	NA	NA	NA	NA	NA	NA	NA		NA	18	NA	0.70	321		
PAUWJB		0	0.33								0.96	0						Gain							3	8	0.12	0.31	576		
PASFSG		0.49	0.4												MAX (0.85)/COBLL1 (0)	MAX (0.76)/COBLL1 (0.51)	Gain	Gain	CN LOH	CN LOH	Gain	Gain	Gain		8	12	0.31	0.47	238		
PATAUM		0	0.41									del			DIS3 (0.35); CHD4 (0.28)	DIS3 (0.33); CHD4 (0.39)		Gain	CN LOH	CN LOH			Gain	Gain		14	11	0.54	0.43	178	
PASSUR		0.49	0.57															Gain	Gain	CN LOH	CN LOH		Gain	Gain		11	24	0.43	0.93	386	
PAWRAM		0	0.61															Gain	Gain	CN LOH	CN LOH		Gain	Gain		1	2	0.04	0.08	196	
PAWPXB		0.39	0.77															Gain	Gain	CN LOH	CN LOH		Gain	Gain		10	3	0.39	0.12	63	
PATFWM					0.14	0									TERT (0.48)	TERT (0.45)		Gain		CN LOH	CN LOH					3	9	0.12	0.35	1266	
PAWWUW					0.97	0.74							0.42	0.29						CN LOH	CN LOH					4	5	0.16	0.19	174	
PAVGSZ					1	0.95					del	del			TCF12 (0)	TCF12 (0.39)			Gain	CN LOH	CN LOH					12	26	0.47	1.01	202	
PAYHJX					1	1														CN LOH	CN LOH					4	3	0.16	0.12	199	
PAUGMT											del	del						Gain	Gain	LOSS	LOSS	Gain	Gain	Gain		12	10	0.47	0.39	762	
PAVFAW					del	del												Gain	Gain			Gain				16	12	0.62	0.47	413	
PASYKN					del	del					0.14	0						Gain	Gain							6	8	0.23	0.31	427	
PARDMN							0.55	0							DIS3 (0)	DIS3 (0.22)		Gain				Gain	Gain	Gain		12	26	0.47	1.01	3788	
PAYTJD							0.48	0.47										Gain				Gain	Gain	Gain	Gain	11	15	0.43	0.58	375	
PAZEPC							0.47	0.56																		2	3	0.08	0.12	362	
PAWAYI											0	0.2														6	3	0.23	0.12	449	
PATNLF											del	del						Gain	Gain		LOSS	Gain	Gain			3	6	0.12	0.23	273	
PATIFC																		Gain	Gain			Gain	Gain			20	19	0.78	0.74	244	
PAZMHH											0.86	0			MAPKB1 (0);TCF12 (0.57)	MAPKB1 (0.39)/TCF12 (0.49)		Gain	CN LOH	CN LOH	Gain	Gain				19	44	0.74	1.71	175	
PAUUFW													0.32	0.47						CN LOH	CN LOH					6	7	0.23	0.27	127	
PAXMWW															TERT (0.45); CHD4 (0.41)	TERT (0.38); CHD4 (0.31)		Gain				Gain				10	19	0.39	0.74	1204	
PAUSLU															DICER (0.53)	DICER 1 (0.81)		Gain		CN LOH		Gain		Gain		7	13	0.27	0.50	701	
PAVAUX															MLLT1 (0.32)	MLLT1 (0.49)				CN LOH						4	5	0.16	0.19	378	
PAYXAD															TERT (0.22); COBLL1 (0)	COBLL1 (0.17)						Gain				3	19	0.12	0.74	262	
PARZBT															HCFC1 (0)	HCFC1 (0.94)		Gain	Gain			Gain		Gain		7	23	0.27	0.89	626	
PAVLIN															NONO (1)	NONO (1)		Gain	Gain			Gain	Gain	Gain	Gain	7	16	0.27	0.62	432	
PAYJBH															RBL1 (0)	RBL1 (0.33)		Gain	Gain			Gain	Gain			12	45	0.47	1.74	302	
PARSKN																		Gain	Gain	CN LOH	CN LOH	Gain	Gain	Gain	Gain	11	33	0.43	1.28	2485	
PASBZW																		Gain	Gain	CN LOH	CN LOH	Gain		Gain	Gain	6	22	0.23	0.85	953	
PATXPY																			Gain	CN LOH	CN LOH	Gain	Gain			5	15	0.19	0.58	293	
PATYFE																		Gain	Gain	CN LOH	CN LOH	Gain	Gain	Gain	Gain	5	25	0.19	0.97	197	
PAUWCD																										4	23	0.16	0.89	94	
PAWARG																		Gain	Gain			Gain	Gain	Gain	Gain	3	2	0.12	0.08	192	
PAWHSE																				CN LOH	CN LOH	Gain	Gain	Gain	Gain	10	12	0.39	0.47	126	
PAXCHH																				CN LOH	CN LOH					2	2	0.08	0.08	716	
PAXCHI																		Gain	Gain	CN LOH		Gain	Gain		Gain	11	10	0.43	0.39	498	
PAYCFB																		Gain	Gain		CN LOH	Gain	Gain	Gain		5	9	0.19	0.35	350	

Supplemental Figure 1: Recurrent genetic abnormalities of Discovery Set Patients (expanded from Figure 1).

The SNVs and structural variants and segmental copy number changes identified in at least 2 patients within the primary (P) and relapse (R) tumors are given for each patient; the allelic fraction of the alt allele is provided as the number in each box, “del” and “dup” indicate the presence of structural deletions and duplications, respectively. Patient sample IDs (left) highlighted in orange are those for which the primary sample lacked mutations in genes identified in Table 1. Copy number data for the primary (P) and relapse (R) for selected loci are provided; those fields in pink indicate gain, those in green indicate copy neutral loss of heterozygosity, and those with loss are in yellow. Fields in grey indicate those primary tumor specimens that were not available for analysis. The number of exonic mutations, the tumor mutation burden (TMB), and the event-free survival (EFS) is provided at the right.